FDA Grants Priority Review for Padcev Plus Keytruda in Bladder Cancer Treatment

Why It Matters

The approval would give clinicians a highly effective, cisplatin‑free peri‑operative option, expanding treatment access and improving survival for a large segment of bladder‑cancer patients.

Key Takeaways

• FDA grants Priority Review for Padcev‑Keytruda combo in MIBC
• EV‑304 trial cut recurrence risk by 47% versus chemo
• Pathologic complete response rose to 55.8% compared with 32.5%
• Benefit observed regardless of patients’ cisplatin eligibility
• Combination may shift peri‑operative bladder cancer standard of care

Pulse Analysis

Bladder cancer remains one of the most lethal urologic malignancies, with muscle‑invasive disease accounting for the majority of deaths. Historically, curative intent has hinged on cisplatin‑based neoadjuvant chemotherapy followed by cystectomy, but up to half of patients are ineligible due to renal dysfunction, hearing loss, or other comorbidities. This therapeutic gap has spurred intense research into targeted and immunologic approaches that can deliver comparable efficacy without the toxicities of platinum agents.

The EV‑304 (KEYNOTE‑B15) trial enrolled over 800 patients and compared peri‑operative Padcev plus Keytruda against the standard gemcitabine‑cisplatin regimen. The combination achieved a statistically significant 47% reduction in the composite endpoint of recurrence, progression, or death, and a 35% mortality reduction, while delivering a 55.8% pathologic complete response rate—well above the 32.5% seen with chemotherapy. Mechanistically, Padcev’s Nectin‑4‑directed antibody‑drug conjugate delivers a cytotoxic payload directly to tumor cells, and Keytruda’s PD‑1 blockade amplifies immune surveillance, creating a synergistic attack that appears effective across cisplatin eligibility groups.

Regulatory momentum is strong: the FDA’s Priority Review designation accelerates the decision timeline to August 17, 2026, and parallel submissions are underway in Europe and Asia. For Astellas and Pfizer, approval would unlock a sizable market, given that roughly 70,000 new MIBC cases arise annually in the U.S. alone. Beyond revenue, the therapy could reshape clinical pathways, positioning an ADC‑immunotherapy duo as the new peri‑operative benchmark and prompting competitors to explore similar combination strategies in other solid tumors.